Time-to-reach STRIDE-II targets and time-to-first flare were assessed over 52 weeks using disease activity indices, inflammatory biomarkers (CRP, FC), and endoscopy.<h4>Results</h4>Seventy-four patients were included (37 Crohn's disease [CD], 37 ulcerative colitis [UC]). This evidence concerns the gene CRP and ulcerative colitis.